Genomma Lab Internacional SAB de CV
BMV:LABB
Operating Margin
Genomma Lab Internacional SAB de CV
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| MX |
|
Genomma Lab Internacional SAB de CV
BMV:LABB
|
23.4B MXN |
21%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
838.8B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
375.1B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
213.9B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.6B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
164.6B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
214.1B USD |
35%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
134.8B USD |
25%
|
Genomma Lab Internacional SAB de CV
Glance View
Nestled amid the dynamic landscape of the Mexican pharmaceutical and personal care market, Genomma Lab Internacional SAB de CV has carved a distinct niche for itself since its inception in 1996. The company, recognized for its innovative approach to marketing and product distribution, operates with a dual business model that focuses both on over-the-counter (OTC) medications and a slew of personal care products. This strategic diversification has enabled Genomma Lab to tap into a broad array of consumer needs, expanding its reach beyond the confines of Mexico to a wide array of markets across the Latin American region and beyond. By leveraging a robust distribution network, which includes traditional retailers and modern trade channels, Genomma ensures that its products – from headache remedies to skincare solutions – are easily accessible to consumers, thereby driving consistent revenue growth. Central to Genomma Lab's success is its ability to blend strategic marketing prowess with an agile supply chain. The company's marketing campaigns are meticulously crafted, often highlighting the efficacy and trustworthiness of its products, which resonates well with a cost-sensitive yet quality-oriented consumer base. Furthermore, Genomma Lab thrives on an innovative product pipeline that sees continual introductions and adaptations in response to changing market demands. This commitment to innovation is complemented by cost efficiency in its operations, allowing the company to maintain competitive pricing. With an entrenched brand presence and a solid track record of adaptability, Genomma Lab continues to bolster its market position, focusing on both organic growth and strategic alliances to propel its evolution in the global marketplace.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Genomma Lab Internacional SAB de CV's most recent financial statements, the company has Operating Margin of 21.4%.
You don't have any saved screeners yet